NOPR Requests Reconsideration of NCA for PET (FDG) for Oncologic Indications

September 17, 2012

NOPR Requests Reconsideration of NCA for Positron Emission Tomography (FDG) for Oncologic Indications

On July 20, 2012, The National Oncologic PET Registry (NOPR) Working Group submitted a formal request to the Centers for Medicare and Medicaid Services (CMS), asking that it reconsider the current National Coverage decision on FDG-PET and to end the NOPR data collection requirements for FDG-PET for the remaining cancers/indications still reimbursed only under coverage with evidence development.  On September 12, 2012, CMS initiated its review of this request (see National Coverage Analysis (NCA) Tracking Sheet for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4) for more information).

It is critical that CMS receives comments in support of the proposed expansion of PET coverage, especially evidence-based comments submitted by treating physicians recognized as academic leaders. CMS is looking for any additional evidence (not just testimonial) that will influence its final decision.  As a result, we are asking SNMMI members to ask your referring physicians to send supporting comments to CMS.

These referring physician comments should emphasize how PET helps the referring physician to manage his/her patients more effectively.  To help with letter composition, we have attached a document discussing the keys to an effective CMS comment letter.  Additionally, we have attached NOPR’s request for reconsideration.

At this time, CMS is soliciting comments on NOPR’s request.  The public comment period will be open for 30 days, until October 12, 2012. Comments can be submitted here

keys to an effective CMS comment letter

NOPR’s request for reconsideration